Prospective Translational Study Investigating Possible Molecular prEdictors of Resistance to First-Line pazopanIb

NCT04462445 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DRUG: Pazopanib

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano